A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.